Provendoc
A GxP-compliant provenance layer that intercepts AI-generated regulatory documents from any tool, logs the prompt, model, reviewer and timestamp, stores an immutable Part 11 receipt, and turns it all into FDA audit-ready reports.
A mid-market pharma quality lead just learned their teams are drafting CSR sections, deviation reports and AE narratives with Yseop, Claude and Copilot — and none of it leaves a defensible trail. When an auditor asks who wrote a sentence in a submitted document, what model produced it, and who reviewed it, the honest answer today is a shrug. 21 CFR Part 11 expects an immutable answer, and the AI-doc tools that generated the text are not built to be the neutral witness for a competitor's output. That gap is the worst kind: invisible until an inspection makes it expensive.
Quality and regulatory affairs at a mid-market pharma (roughly 100-1000 FTE) who already owns a GxP compliance budget and is personally accountable when an audit trail can't answer for an AI-written document.
Pharma races to adopt AI doc generation while Part 11 demands immutable provenance — tool-agnostic interception across Yseop, AlphaLife, Peer AI and in-house models resolves what no single AI-doc vendor can.
FDA Elsa hallucinations, a BioSpace audit-trail signal, and a confirmed read that Claude-for-Life-Sciences enterprise lock-in is 12-18 months out all frame an explicitly open window.
Three cross-reference mentions and seven inbound links with a GPT+Grok Q3 convergence, but the provenance-receipt pattern mostly shows up as siblings rather than one strongly converged signal.
The productive tension is the standout: pharma is racing to adopt AI document generation at the exact moment Part 11 demands immutable provenance, and a tool-agnostic interception layer resolves a conflict no single AI-doc vendor can. The buyer function and segment are clear, the incumbent-blindspot argument is structural (a vendor can't be the neutral witness for a rival's output), and the need is genuinely newborn — AI-generated regulatory documents only went mainstream in 2025-2026.
Convergence is the soft spot — the provenance-receipt pattern recurs across many runs but mostly as siblings rather than as one strongly converged signal, and the buyer title is implied rather than named. The execution reality also drags: GxP vendor qualification (IQ/OQ audits) adds per-customer validation overhead, and Part 11 compliance claims invite audit scrutiny of the product itself.
Genesis doesn't invent in isolation — Provendoc shares architecture with, or powers, these ideas.
Discussion
No comments yet — be the first to weigh in.